Mavyret is the newly approved hepatitis C medications.
The Food and Drug Administration (FDA) recently approved AbbVie’s Mavyret, the newest treatment for chronic hepatitis C virus infection for people without cirrhosis or with compensated cirrhosis. Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken once daily (three tablets for a total daily dose of glecaprevir 300 mg and pibrentasvir 120 mg) to treat genotypes 1 through 6.
What You Need to Know about Mavyret
AbbVie’s Mavyret is one pill containing two drugs. Both are direct-acting antivirals (DAAs) which means they directly interfere with hepatitis C virus replication. One drug, glecaprevir is an HCV NS3/4A protease inhibitor. The second drug is pibrentasvir, an NS5A inhibitor.
Read full article: AbbVie’s Mavyret: The Hepatitis C Treatment We’ve Been Waiting For? – Hep
|Read Full Article: AbbVie’s Mavyret: The Hepatitis C Treatment We’ve Been Waiting For? – Hep|